Retifanlimab clinical trials
Also written INCMGA00012, MGA012 and Zynyz.
How each study uses retifanlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the retifanlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Mar 2023 · ZYNYZ · BLA 761334 (FDA, Drugs@FDA)
- European Union
- 19 Apr 2024 · Zynyz · EMEA/H/C/006194 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
44 studies that test it; most in 2020 (11)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 11 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 28
Incyte Corporation (9) · MacroGenics (5) · Memorial Sloan Kettering Cancer Center (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Washington University School of Medicine (2) · M.D. Anderson Cancer Center (2) · University of Washington (1) · Institut Bergonié (1)
Often tested with
Tested in the same studies.
Epacadostat (3) · Tuparstobart (3) · Verzistobart (3) · Tebotelimab (3) · Allogeneic Autophagosome-enriched Vaccine DPV-001 (1) · Pelareorep (1) · Pemetrexed (1) · Cisplatin (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test retifanlimab.
- Dec 2026PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent ChemoradiotherapyPhase 2 · Asan Medical Center
- Jun 2027Palbociclib and INCMGA00012 in People With Advanced LiposarcomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Sep 2027Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaPhase 1/2 · Memorial Sloan Kettering Cancer Center
- Oct 2027Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)Phase 1/2 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses retifanlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 44
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingPhase 2Scott R. Plotkin, MD, PhDNCT04374305Written as RetifanlimabHow we know
- A Study of Retifanlimab After Chemoradiation in People With Anal CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07927998Written as RetifanlimabHow we know
- Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT06149481Written as RetifanlimabHow we know
- ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1Not yet recruitingPhase 1/2University of Wisconsin, MadisonNCT07472322Written as ASTX727 + retifanlimabHow we know
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT04577014Written as RetifanlimabHow we know
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)RecruitingPhase 2Lund University HospitalNCT06389799Written as RetifanlimabHow we know
- Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingPhase 2Polly A. Niravath, MDNCT07772245Written as RetifanlimabHow we know
- ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal CancerRecruitingPhase 2Jennifer DorthNCT07425054Written as RetifanlimabHow we know
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasRecruitingPhase 1/2Mayo ClinicNCT07468136Written as RetifanlimabHow we know
- Retifanlimab and Ruxolitinib In Solid MalignanciesRecruitingPhase 1/2University of California, San DiegoNCT07219576Written as RetifanlimabHow we know
- Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With GlioblastomaRecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05083754Written as RetifanlimabHow we know
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaActive, not recruitingPhase 1/2University of WashingtonNCT05455697Written as RetifanlimabHow we know
- Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)Active, not recruitingPhase 2Institut BergoniéNCT04968106Written as INCMGA00012How we know
- A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)SuspendedPhase 1M.D. Anderson Cancer CenterNCT06959537Written as RetifanlimabHow we know
- Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).CompletedPhase 3Incyte CorporationNCT04472429Written as retifanlimabHow we know
- Palbociclib and INCMGA00012 in People With Advanced LiposarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04438824Written as INCMGA00012How we know
- Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCCActive, not recruitingPhase 1Providence Health & ServicesNCT04470024Written as INCMGA00012How we know
- Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedPhase 3Incyte CorporationNCT04205812Written as RetifanlimabHow we know
- Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.CompletedPhase 2Incyte CorporationNCT04463771Written as retifanlimabHow we know
- PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent ChemoradiotherapyActive, not recruitingPhase 2Asan Medical CenterNCT04494009Written as INCMGA00012How we know
See all 44 studies that test retifanlimab →
Given beside what is tested · 25 — retifanlimab is usual care or a partner of the new treatment
- 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)RecruitingPhase 1Anwaar SaeedNCT06896188Written as RetifanlimabHow we know
- A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered GliomaRecruitingEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06610682Written as RetifanlimabHow we know
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.RecruitingPhase 3BriaCell Therapeutics CorporationNCT06072612Written as RetifanlimabHow we know
- Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PCNot yet recruitingPhase 2Massachusetts General HospitalNCT07765836Written as RetifanlimabHow we know
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationRecruitingPhase 1Incyte CorporationNCT06179160Written as RetifanlimabHow we know
- Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1/2OHSU Knight Cancer InstituteNCT06320405Written as RetifanlimabHow we know
- NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal CancerNot yet recruitingPhase 2Northwell HealthNCT07677579Written as RetifanlimabHow we know
- All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant GliomaRecruitingPhase 2Stephen Bagley, MD, MSCENCT05345002Written as RetifanlimabHow we know
- Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent GlioblastomaRecruitingPhase 2Academic and Community Cancer Research UnitedNCT06160206Written as RetifanlimabHow we know
- Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)RecruitingPhase 2Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT05177133Written as RetifanlimabHow we know
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2Incyte Biosciences International SàrlNCT05287113Written as RetifanlimabHow we know
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingPhase 1University of Southern CaliforniaNCT04387084Written as RetifanlimabHow we know
- A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsTerminatedPhase 1/2Incyte CorporationNCT06873789Written as RetifanlimabHow we know
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell CarcinomaActive, not recruitingPhase 2University of WashingtonNCT06056895Written as RetifanlimabHow we know
- Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent GlioblastomaActive, not recruitingPhase 2University of PennsylvaniaNCT04225039Written as INCMGA00012How we know
- Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )TerminatedPhase 1/2Ariceum Therapeutics GmbHNCT06939036Written as RetifanlimabHow we know
- A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced MalignanciesTerminatedPhase 1Incyte CorporationNCT03522142Written as INCMGA00012How we know
- Study of INCA 0186 in Subjects With Advanced Solid TumorsTerminatedPhase 1Incyte CorporationNCT04989387Written as RetifanlimabHow we know
- Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedPhase 1MacroGenicsNCT02475213Written as retifanlimabHow we know
- INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedPhase 1Incyte CorporationNCT04580485Written as INCMGA00012How we know
Showing 20 of 25.
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
- A Study of Retifanlimab After Chemoradiation in People With Anal CancerNov 10, 2026NCT07927998
Codes
What other systems call retifanlimab · ClinicalTrials.gg INT002166
- MeSH (NLM) C000731936retifanlimabOne source NLM
- UNII (FDA) 2Y3T5IF01ZRETIFANLIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q117349369retifanlimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C142168RetifanlimabOne source FDA
- DrugBank DB15766One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731936 | retifanlimab | One source NLM |
| UNII (FDA) | 2Y3T5IF01Z | RETIFANLIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q117349369 | retifanlimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C142168 | Retifanlimab | One source FDA |
| DrugBank | DB15766 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.